or Try an Advanced Search...

    Protein Kinase Inhibitor Stocks List

    Symbol Grade Name % Change
    ALLR F Allarity Therapeutics, Inc. 7.87
    NTBL F Notable Labs, Ltd. -0.65
    BBIO D BridgeBio Pharma, Inc. 5.50
    AVBP D ArriVent BioPharma, Inc. 1.03
    PRLD D Prelude Therapeutics Incorporated -1.06
    PBYI D Puma Biotechnology Inc -2.37
    ACLX D Arcellx, Inc. 4.32
    COGT D Cogent Biosciences, Inc. 6.62
    EXEL B Exelixis, Inc. -6.54
    ELVN A Enliven Therapeutics, Inc. 4.08
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Cancer Tyrosine Kinase Biotechnology Tyrosine Kinase Receptors Biopharmaceutical Solid Tumors Acute Myeloid Leukemia Cancer Treatment Chronic Myeloid Leukemia Clinical Medicine Enzymes Her2 Myelodysplastic Syndrome Non Small Cell Lung Cancer Organ Systems Orphan Drug Small Molecule Therapies Treatment Of Cancer Achondroplasia Advanced Breast Cancer

    Related ETFs - A few ETFs which own one or more of the above listed Protein Kinase Inhibitor stocks.

    Symbol Grade Name Weight
    IDNA C iShares Genomics Immunology and Healthcare ETF 6.56
    CNCR C Loncar Cancer Immunotherapy ETF 5.89
    XBI C SPDR S&P Biotech ETF 3.63
    BBP C BioShares Biotechnology Products Fund 3.56
    FBT D First Trust Amex Biotech Index Fund 3.43
    View all Protein Kinase Inhibitor ETFs...
    Compare ETFs
    Compare BBP to FBT Compare CNCR to XBI Compare XBI to FBT

        Protein Kinase Inhibitor Stocks Recent News

        Date Stock Title
        May 1 EXEL Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
        May 1 BBIO Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
        May 1 EXEL Q1 2024 Exelixis Inc Earnings Call
        May 1 EXEL Exelixis Inc (EXEL) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...
        May 1 EXEL Exelixis (EXEL) Q1 2024 Earnings Call Transcript
        May 1 EXEL Exelixis, Inc. (EXEL) Q1 2024 Earnings Call Transcript
        Apr 30 EXEL Exelixis down 7% as Q1 financial results disappoint
        Apr 30 EXEL Exelixis (EXEL) Reports Q1 Earnings: What Key Metrics Have to Say
        Apr 30 EXEL Exelixis Inc (EXEL) Q1 2024 Earnings: Mixed Results Amidst Restructuring Efforts
        Apr 30 EXEL Exelixis Non-GAAP EPS of $0.17 misses by $0.12, revenue of $425.2M misses by $35.27M
        Apr 30 EXEL Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
        Apr 29 EXEL Exelixis Q1 2024 Earnings Preview
        Apr 29 ALLR Allarity regains compliance with NASDAQ minimum bid price requirement
        Apr 29 PBYI Is Puma Biotechnology, Inc. (NASDAQ:PBYI) A High Quality Stock To Own?
        Apr 29 ALLR Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
        Apr 26 PBYI What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
        Apr 26 EXEL Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
        Apr 26 EXEL Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
        Apr 25 BBIO Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
        Related Industries: Biotechnology
        Related Stock Lists: Cancer Tyrosine Kinase Biotechnology Tyrosine Kinase Receptors Biopharmaceutical Solid Tumors Acute Myeloid Leukemia Cancer Treatment Chronic Myeloid Leukemia Clinical Medicine Enzymes Her2 Myelodysplastic Syndrome Non Small Cell Lung Cancer Organ Systems Orphan Drug Small Molecule Therapies Treatment Of Cancer Achondroplasia Advanced Breast Cancer
        Protein Kinase Inhibitor

        Protein kinase inhibitors are drugs that block the activity of one or more protein kinases. Protein kinases are enzymes that add phosphate groups to proteins, which can alter their activity and function. Protein kinase inhibitors are used to treat a variety of diseases, including cancer, inflammation, and autoimmune disorders.

        Browse All Tags